Eiko Lifesciences has filed its 49th annual report for FY26 and confirmed its annual general meeting is set for September 22, 2026. The filing marks the completion of statutory disclosures for the financial year.

The board meeting held on August 24, 2026, approved these agenda items pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The AGM will be conducted via video conferencing or other audio-visual means.

Board Composition Changes

Suraj Mahadev Gaikwad was appointed as an additional independent and non-executive director on August 24, 2026. He will hold office until the ensuing AGM, after which he will serve as an independent director for a five-year term, subject to shareholder approval. Mr. Gaikwad brings over seven years of experience in accountancy and business management and holds a commerce degree.

The board also noted the resignation of independent director Hasti Doshi, effective August 24, 2026, citing other career commitments. Her term was originally scheduled to conclude on September 3, 2029. Additionally, the board recommended the re-appointment of Bhavesh Dhirajlal Tanna as a director liable to retire by rotation. Mr. Tanna, who holds a 5.86% stake in the company, has over 24 years of experience in investment and financial consultancy.

Related-Party Transactions

Shareholders are asked to approve material related-party transactions expected in FY27. These transactions, deemed to be in the ordinary course of business and at arm’s length, involve loans, advances, and operational dealings with promoters, their associates, and subsidiaries.

Promoter group entities holding shares will not vote on this resolution as per Regulation 23(7) of the SEBI Listing Regulations.

Annual General Meeting Details

The 49th AGM is scheduled for Tuesday, September 22, 2026, at 4:00 pm. The meeting venue is deemed to be the registered office at Thane West. Shravan Gupta, a practicing company secretary, was appointed as the scrutinizer to oversee the e-voting process. M/s Bigshare Services Pvt Ltd will serve as the service provider for conducting e-voting and video conferencing facilities.

Remote e-voting will begin on September 19, 2026, at 9:00 am and end on September 21, 2026, at 5:00 pm. Shareholders must hold shares as on the cut-off date of September 16, 2026, to be eligible to vote. Members wishing to speak at the AGM must register by September 18, 2026, at 5:00 pm.

Eiko Lifesciences has accepted the resignation of Ms. Hasti Doshi from the position of Independent Director on its Board. The change is effective from the closing of business hours on August 24, 2026.

Ms. Doshi, identified by DIN 10757758, cited other career commitments requiring her time and attention as the reason for stepping down. Her original term was scheduled to conclude on September 3, 2029.

Board Approval and Regulatory Compliance

The Board of Directors of Eiko Lifesciences considered and approved the resignation during its meeting held on August 24, 2026. The company disclosed the development pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Chintan Doshi, the Company Secretary and Compliance Officer, confirmed the acceptance to the BSE Limited.

Resignation Details

In her resignation letter, Ms. Doshi confirmed that there are no material reasons for her departure other than the stated career commitments. She thanked the Board and the company for the support extended during her tenure.

Ms. Doshi does not hold directorships in any other listed entities. The Board has been requested to update statutory records and inform relevant regulatory authorities accordingly.